In vitro drug interaction between diflunisal and indomethacin via glucuronidation in humans

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 6, 2006, Pages 267-273

  Mano, Yuji ^a   Usui, Takashi ^a   Kamimura, Hidetaka ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Diflunisal; Drug interaction; Glucuronidation; Human; Indomethacin

Indexed keywords

DIFLUNISAL; INDOMETACIN;

ARTICLE; CONCENTRATION RESPONSE; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTESTINE; KINETICS; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; MICROSOME;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIFLUNISAL; DRUG INTERACTIONS; GLUCURONIDES; HUMANS; INDICATORS AND REAGENTS; INDOMETHACIN; INTESTINES; MICROSOMES;

EID: 33749334695     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.507     Document Type: Article

References (23)

1. Van Hecken A, Verbesselt R, Tjandra-Maga TB, De Schepper PJ. Pharmacokinetic interaction between indomethacin and diflunisal. Eur J Clin Pharmacol 1989; 36: 507-512.
2. Helleberg L. Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet 1981; 6: 245-258.
3. Mano Y, Usui T, Kamimura H. In vitro inhibitory effects of non-steroidal antiinflammatory drugs on UDP-glucuronosyltransferase 1A1-catalysed estradiol 30-glucuronidation in human liver microsomes. Biopharm Drug Dispos 2005; 26: 35-39.
4. Mano Y, Usui T, Kamimura H. In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9 - potent inhibition by niflumic acid. Biopharm Drug Dispos 2006; 27: 1-6.
5. Vietri M, Pietrabissa A, Mosca F, Pacifici GM. Mycophenolic acid glucuronidation and its inhibition by nonsteroidal anti-inflammatory drugs in human liver and kidney. Eur J Clin Pharmacol 2000; 56: 659-664.
6. Addison RS, Parker-Scott SL, Eadie MJ, Hooper WD, Dickinson RG. Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers. Eur J Clin Pharmacol 2000; 56: 715-721.
7. Lin JH. Species differences in protein binding of diflunisal. Drug Metab Dispos 1989; 17: 221-223.
8. Vietri M, De Santi C, Pietrabissa A, Mosca F, Pacifici GM. Inhibition of human liver phenol sulfotransferase by nonsteroidal anti-inflammatory drugs. Eur J Clin Pharmacol 2000; 56: 81-87.
9. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40: 581-616.
10. Mano Y, Usui T, Kamimura H. Effects of β-estradiol and propofol on the 4-methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9. Biopharm Drug Dispos 2004; 25: 339-344.
11. Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005; 33: 1027-1035.
12. Watanabe Y, Nakajima, M, Yokoi T. Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 2002; 30: 1462-1469.
13. Cheng Z, Radominska-Pandya A, Tephly TR. Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 1999; 27: 1165-1170.
14. Soars MG, Ring BJ, Wrighton SA. The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 2003; 31: 762-767.
15. Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 1998; 26: 261-266.
16. Sabolovic N, Heydel JM, Li X, et al. Carboxyl nonsteroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract. Biochim Biophys Acta 2004; 1675: 120-129.
17. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502.
18. Soars MG, Burchell B, Riley RJ. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 2002; 301: 382-390.
19. Alvan G, Orme M, Bertilsson L, Ekstrand R, Palmer L. Pharmacokinetics of indomethacin. Clin Pharmacol Ther 1975; 18: 364-373.
20. Kwan KC, Breault GO, Umbenhauer ER, McMahon FG, Duggan DE. Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man. J Pharmacokinet Biopharm 1976; 4: 255-280.
21. Bhat R, Vidyasagar D, Fisher E, et al. Pharmacokinetics of oral and intravenous indomethacin in preterm infants. Dev Pharmacol Ther 1980; 1: 101-110.
22. Hucker HB, Zacchei AG, Cox SV, Brodie DA, Cantwell NHR. Studies on the absorption, distribution and excretion of indomethacin in various species. J Pharmacol Exp Ther 1966; 153: 237-249.
23. Terhaag B, Hermann U. Biliary elimination of indomethacin in man. Eur J Clin Pharmacol 1986; 29: 691-695.